(Q38093509)

English

Role of interleukin-28B polymorphism as a predictor of sustained virological response in patients with chronic hepatitis C treated with triple therapy: a systematic review and meta-analysis

scientific article published on May 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

28 August 2017

0 references

Role of interleukin-28B polymorphism as a predictor of sustained virological response in patients with chronic hepatitis C treated with triple therapy: a systematic review and meta-analysis (English)

1 reference

Europe PubMed Central

28 August 2017

0 references

systematic review

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

chronic hepatitis C

1 reference

based on heuristic

inferred from title

chronic hepatitis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Simona Bota

1

1 reference

Europe PubMed Central

28 August 2017

Ioan Sporea

2

1 reference

Europe PubMed Central

28 August 2017

Roxana Şirli

3

1 reference

Europe PubMed Central

28 August 2017

Adriana Maria Neghină

4

1 reference

Europe PubMed Central

28 August 2017

Alina Popescu

5

1 reference

Europe PubMed Central

28 August 2017

Mihnea Străin

6

1 reference

Europe PubMed Central

28 August 2017

publication date

1 May 2013

1 reference

Europe PubMed Central

28 August 2017

Clinical Drug Investigation

1 reference

Europe PubMed Central

28 August 2017

33

1 reference

Europe PubMed Central

28 August 2017

5

1 reference

Europe PubMed Central

28 August 2017

325-331

1 reference

Europe PubMed Central

28 August 2017

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0074-0

21 January 2018

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0074-0

21 January 2018

High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0074-0

21 January 2018

Pegylated interferon and ribavirin combination therapy for chronic hepatitis C virus infection in patients with Child-Pugh Class A liver cirrhosis.

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0074-0

21 January 2018

Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0074-0

21 January 2018

Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0074-0

21 January 2018

Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0074-0

21 January 2018

Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-α and ribavirin

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0074-0

21 January 2018

Telaprevir for previously treated chronic HCV infection

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0074-0

21 January 2018

Telaprevir: an NS3/4A protease inhibitor for the treatment of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0074-0

21 January 2018

Boceprevir for untreated chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0074-0

21 January 2018

Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0074-0

21 January 2018

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0074-0

21 January 2018

Bias in meta-analysis detected by a simple, graphical test

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0074-0

21 January 2018

IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0074-0

21 January 2018

Amino acid substitution in HCV core/NS5A region and genetic variation near IL28B gene affect treatment efficacy to interferon plus ribavirin combination therapy.

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0074-0

21 January 2018

Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir.

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0074-0

21 January 2018

Factors that predict response of patients with hepatitis C virus infection to boceprevir

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0074-0

21 January 2018

Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin.

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0074-0

21 January 2018

Boceprevir for previously treated chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0074-0

21 January 2018

Telaprevir for retreatment of HCV infection

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0074-0

21 January 2018

Telaprevir for previously untreated chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0074-0

21 January 2018

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0074-0

21 January 2018

Estimating the likelihood of sustained virological response in chronic hepatitis C therapy.

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0074-0

21 January 2018

Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0074-0

21 January 2018

Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0074-0

21 January 2018

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0074-0

21 January 2018

The Correlation of Il28B Genotype With Sustained Virologic Response In Romanian patients With Chronic Hepatitis C.

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0074-0

21 January 2018

The role of genetic markers in hepatitis C virus therapy: a major step for individualized care

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0074-0

21 January 2018

Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection.

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0074-0

21 January 2018

Interferon signaling and treatment outcome in chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0074-0

21 January 2018

Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium

1 reference

https://pubmed.ncbi.nlm.nih.gov/23532802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A new standard of care for the treatment of chronic HCV infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/23532802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Response to standard of care antiviral treatment in patients with HCV liver cirrhosis - a systematic review

1 reference

https://pubmed.ncbi.nlm.nih.gov/23532802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirin

1 reference

https://pubmed.ncbi.nlm.nih.gov/23532802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Single nucleotide polymorphisms of the IL28B and sustained virologic response of patients with chronic hepatitis C to PEG-interferon/ribavirin therapy: A meta-analysis: Meta-analysis of IL28B.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23532802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Outcome of antiviral treatment in patients with chronic genotype 1 HCV hepatitis. A retrospective study in 507 patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23532802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S40261-013-0074-0

1 reference

Europe PubMed Central

28 August 2017

1 reference

Europe PubMed Central

28 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38093509&oldid=1740842732"